Karyopharm CEO sells common stock for $3,175

Published 01/07/2025, 04:04 PM
KPTI
-

This transaction was conducted under a durable automatic sale instruction plan that Paulson adopted in June 2021. The sale was broker-assisted and aimed at covering the withholding tax liability incurred upon the vesting of restricted stock units, rather than representing a discretionary trade by Paulson. Following this transaction, Paulson retains ownership of 1,124,257 shares in the company. For deeper insights into KPTI's financial health and detailed analysis, including 10 key ProTips, check out the comprehensive Pro Research Report available on InvestingPro. For deeper insights into KPTI's financial health and detailed analysis, including 10 key ProTips, check out the comprehensive Pro Research Report available on InvestingPro.

This transaction was conducted under a durable automatic sale instruction plan that Paulson adopted in June 2021. The sale was broker-assisted and aimed at covering the withholding tax liability incurred upon the vesting of restricted stock units, rather than representing a discretionary trade by Paulson. Following this transaction, Paulson retains ownership of 1,124,257 shares in the company.

In other recent news, Karyopharm Therapeutics (NASDAQ:KPTI) has reported significant developments in its operations. The company unveiled updates on its Phase 3 trials, including the SENTRY trial for myelofibrosis and the ECO-042 trial for endometrial cancer, both targeting annual U.S. peak revenues of $1 billion. Karyopharm also reported Q3 2024 revenues of $38.8 million and narrowed its 2024 revenue guidance to $145 million to $155 million.

In addition to these updates, the company announced leadership changes with Lori Macomber appointed as Executive Vice President, Chief Financial Officer, and Treasurer, and Kristin Abate promoted to Vice President, Chief Accounting Officer, and Assistant Treasurer.

These recent developments indicate Karyopharm's ongoing efforts to strengthen its executive team and progress in its clinical trials. The company is preparing for potential rapid launches of selinexor, pending approval, in both myelofibrosis and endometrial cancer markets. Despite a slight decline in net U.S. XPOVIO revenue compared to the previous year, the company maintains consistent growth in net product revenue. These developments reflect Karyopharm's resilience and strategic focus.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.